Drug Trial Radar · NCT02230228
Phase 1 Safety Study of ALK-001 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Apr 2014
Primary completion
Sep 2014
Study completion Feb 2015
Sponsor
- Lead sponsor
- Alkeus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 3, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This protocol is a phase 1 clinical study to assess the safety and pharmacokinetics of ALK-001 in healthy volunteers. Please contact trials@alkeus.com for any questions.
Conditions
- Stargardt Disease
- Age-related Macular Degeneration
- Other Retinal Dystrophies
Interventions
ALK-001 (No generic name)Drug
Daily, oral administration of ALK-001 capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of 4-week daily dosing of ALK-001 in healthy adults.Time frame: 4 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.